ConvaTec Group Plc
BLOCK LISTING SIX MONTHLY RETURN
Date: 28 June 2022
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc Long Term Incentive Plan |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
9,850,000 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
9,850,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc US Employee Stock Purchase Plan |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
290,000 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less : Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
290,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc Share Plan |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
3,000,000 |
|||
|
Plus : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
3,000,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc Deferred Bonus Plan |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
430,000 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
430,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc UK SAYE |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
1,830,000 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
1,830,000 |
|||
|
Equals : Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
|
Name of applicant: |
ConvaTec Group Plc |
|||
|
Name of scheme: |
ConvaTec Group Plc Global SAYE Sub-Plan |
|||
|
Period of return: |
From: |
21 December 2021 |
To: |
20 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
4,600,000 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
4,600,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
0 |
|||
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations, ConvaTec +44 (0)782 644 7807
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com